
Establishment Labs Holdings Inc.: stock overview
Price
$69.96
November 16, 2026Market cap $2.1B
What Ploutos Investor adds for Establishment Labs
Part of Ploutos Investor, €9.99 a month
- The full history: 9 fiscal years, from 2017
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Notes on these figures
- The interest the company pays is far more than the debt we can read would cost, so part of its borrowing is missing from the figures. We leave out the debt, net cash, enterprise value and the multiples built on them.
In short
Establishment Labs had revenue of $264M over the last 12 months and a net loss of $38M. Revenue grew by 20.0% a year on average over the last 5 years. It pays no dividend.
From its SEC filings (latest fiscal year to December 31, 2025) and the price of November 16, 2026.
Its SEC filings- Market cap
- $2.1B
- 29.32M shares
- P/E
- –
- Revenue, 12 months
- $264M
- +20.0% a year over 5 years
- Net margin
- -14.6%
- 2025: -24.2%, above 23% of its industry
Worth knowing
What a holder would want to hear from the company's SEC filings of the last three years. Each with its filing, without comment.
3 fiscal years in figures
Each fiscal year's figures as the company filed them, and the share price at its end.
+13.1% a year over 2 years
Fiscal years in figures
ESTA's revenue, profit, cash flow and dividend with each year-end price, from 2017 to 2022, 6 more fiscal years
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 5 fiscal years.
Key figures
The company's current figures in five groups. Each term is explained behind its ⓘ.
Valuation
- Market cap 3-year median: $1.3B
- $2.1B
- Enterprise value
- –
- P/E
- –
- EV / EBIT
- –
- EV / Revenue
- –
- P/B 3-year median: 38.3
- 131.5
- FCF yield 3-year median: -4.9%
- –
- Earnings yield 3-year median: -6.5%
- –
Profitability
- Gross margin
- 70.2%
- Operating margin
- -6.6%
- Net margin 3-year median: -47.5%
- -14.6%
- ROIC
- -5.0%
- ROIC, 5-year average
- -17.3%
- ROE
- -209.2%
Growth
- Revenue, yearly change
- +27.1%
- EPS, yearly change
- –
- FCF, yearly change
- –
- Revenue, average a year
- +20.0%
The yearly change compares FY2025 with FY2024.
Balance sheet
- Cash
- $76M
- Total debt
- –
- Net cash
- –
- Net debt / EBITDA
- –
- Interest cover
- -0.6x
- Current ratio
- 3.57
Balance sheet of September 30, 2026.
Returns to shareholders
- Dividend yield
- 0.00%
- Buybacks
- –
- Total returned
- 0.00%
- Shares, yearly change
- +1.7%
Against its industry
Where its margins and returns stood in fiscal 2025 among the SEC filers of its industry (SIC code 38).
Gross margin
69.3%
Above 79% of the 161 companies in its industry, and 86% of all.
Operating margin
-18.5%
Above 25% of the 186 companies in its industry, and 15% of all.
Net margin
-24.2%
Above 23% of the 189 companies in its industry, and 12% of all.
ROE
-216.9%
Above 1% of the 174 companies in its industry, and 1% of all.
ROA
-14.3%
Above 26% of the 190 companies in its industry, and 12% of all.
Revenue growth
27.1%
Above 90% of the 186 companies in its industry, and 87% of all.
From the yearly figures every company files with the SEC, for those with revenue of at least $25 million. The industry is the first two digits of the SIC code.
The company at the SEC
How it is registered and when its fiscal year ends.
- Name at the SEC
- ESTABLISHMENT LABS HOLDINGS INC.
- CIK
- 1688757
- Exchange
- NASDAQ
- Industry (SIC)
- 3842 · Orthopedic, Prosthetic & Surgical Appliances & Supplies
- Fiscal year ends
- December 31
- Latest annual report
- December 31, 2025
- Reporting currency
- USD
- Shares
- 29.32M
Other companies: Healthcare
The largest companies of the same sector, each with its own page.
- LLYEli Lilly and Company+0,00%Compare with ESTA
- JNJJohnson & Johnson+0,00%Compare with ESTA
- ABBVAbbVie+0,00%Compare with ESTA
- UNHUnitedHealth+0,00%Compare with ESTA
- MRKMerck & Company+0,00%Compare with ESTA
- AMGNAmgen+0,00%Compare with ESTA
- TMOThermo Fisher Scientific+0,00%Compare with ESTA
- ABTAbbott Laboratories+0,00%Compare with ESTA
The full analysis
What do Establishment Labs's filings show?
These are Establishment Labs's figures. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
What is ESTA's market cap?
Establishment Labs Holdings Inc.'s market cap is $2.1B, at a price of $69.96 on November 16, 2026 and 29.32M shares.
How much revenue does ESTA have?
Establishment Labs had revenue of $264M over the last 12 months. Over the last 5 years it changed by +20.0% a year on average.
Does ESTA pay a dividend?
No. Establishment Labs paid no regular dividend over the last 12 months.
Where do the figures come from?
From Establishment Labs Holdings Inc.'s SEC filings (10-K and 10-Q) and the share price. They hold no analyst estimates and no score, and they are not a recommendation.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.